Silvana Pileggi

Dr. Silvana Pileggi

Medical Genetics, Department of Health Sciences, Università degli Studi di Milano, 20142 Milano, Italy;
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
LCLucia Corrado
Lucia Corrado
SBStefania Battistini
Stefania Battistini
SPSilvana Penco
Silvana Penco
LBLaura Bergamaschi
Laura Bergamaschi
LTLucia Testa
Lucia Testa
SDSandra D'ALfonso
Sandra D'ALfonso

1 January 2013 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
SBS Bacigaluppi
S Bacigaluppi
SRSf Retta
Sf Retta
SPSilvana Pileggi
Silvana Pileggi
Marco Maria FontanellaMarco Maria Fontanella
Marco Maria Fontanella
LGL Goitre
L Goitre
SPS Penco
S Penco

1 September 2016 in Nutrition Research
Verified
Journal Article
Closed access
WWWilliam S William
William S William
SMSerge Masson
Serge Masson
SBSimona Barlera
Simona Barlera
VMValentina Milani
Valentina Milani
SPSilvana Pileggi
Silvana Pileggi
GIGISSI-HF Investigators
GISSI-HF Investigators

27 October 2023 in Circulation Research
Verified
Journal Article
Closed access
DLDuan Liu
Duan Liu
MWMin Wang
Min Wang
VMVishakantha Murthy
Vishakantha Murthy
DMDennis M. McNamara
Dennis M. McNamara
TNThanh Thanh L. Nguyen
Thanh Thanh L. Nguyen
NPNaveen L. Pereira
Naveen L. Pereira
BACKGROUND: Dilated cardiomyopathy (DCM) is a major cause of heart failure and carries a high mortality rate. Myocardial recovery in DCM-related heart failure patients is highly variable, with some patients having little or no response to standard drug therapy. A genome-wide association study may agnostically identify biomarkers and provide novel insight into the biology of myocardial recovery in DCM. METHODS: A genome-wide association study for change in left ventricular ejection fraction was performed in 686 White subjects with recent-onset DCM who received standard pharmacotherapy. Genome-wide association study signals were subsequently functionally validated and studied in relevant cellular models to understand molecular mechanisms that may have contributed to the change in left ventricular ejection fraction. RESULTS: The genome-wide association study identified a highly suggestive locus that mapped to the 5′-flanking region of the CDCP1 (CUB [complement C1r/C1s, Uegf, and Bmp1] domain containing protein 1) gene (rs6773435; P =7.12×10 −7 ). The variant allele was associated with improved cardiac function and decreased CDCP1 transcription. CDCP1 expression was significantly upregulated in human cardiac fibroblasts (HCFs) in response to the PDGF (platelet-derived growth factor) signaling, and knockdown of CDCP1 significantly repressed HCF proliferation and decreased AKT (protein kinase B) phosphorylation. Transcriptomic profiling after CDCP1 knockdown in HCFs supported the conclusion that CDCP1 regulates HCF proliferation and mitosis. In addition, CDCP1 knockdown in HCFs resulted in significantly decreased expression of soluble ST2 (suppression of tumorigenicity-2), a prognostic biomarker for heart failure and inductor of cardiac fibrosis. CONCLUSIONS: CDCP1 may play an important role in myocardial recovery in recent-onset DCM and mediates its effect primarily by attenuating cardiac fibrosis.

24 April 2010 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
SPSilvana Pileggi
Silvana Pileggi
SBSerena Buscone
Serena Buscone
Claudia RicciClaudia Ricci
Claudia Ricci
MPMaria Cristina Patrosso
Maria Cristina Patrosso
AMAlessandro Marocchi
Alessandro Marocchi
SPSilvana Penco
Silvana Penco

2 March 2016 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
MFMaddalena Fratelli
Maddalena Fratelli
MBMarco Bolis
Marco Bolis
MKMami Kurosaki
Mami Kurosaki
MDMartina Dori
Martina Dori
VGValeria Guarnaccia
Valeria Guarnaccia
Enrico GarattiniEnrico Garattini
Enrico Garattini
Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population. . . doi: 10.3109/10428194.2015.1082180